ADMA Biologics is trading 4.11% higher at $10.77 alongside study news; the release did not explicitly link it to the share-price move. - On October 15, 2026, a peer-reviewed report said the optimized IVIG process removed procoagulant impurities, maintained product quality and increased IgG yield. - No thromboembolic-event reports were identified for products made with the process during the evaluated surveillance period. - Markets faced renewed inflation and interest-rate concerns, but these are not established as the reason for the gain; reliable current trading-volume detail was unavailable.